TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/06/2025
Voltar para busca
Dado oficial do USPTO
GRITSTONE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
GRITSTONE
ST13
US500000087748380Classe
5, 9, 42, 44
Pedido
87748380
Registro
6569577
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
02/07/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42, 44
Data de depósito
09/01/2018
Data de registro
23/11/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/11/2021
Última transação
02/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
18/03/2019
Primeiro uso no comércio
18/03/2019
Código do desenho
4
Tipo de titular
03
Localização do titular
Jackson, WY
Examinador
CLARK, ROBERT
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
GRITSTONE BIO, INC.
GRITSTONE BIO, INC.
Gritstone Oncology, Inc.
Representantes
Shauna M. Wertheim The Marbury Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; vaccines; vaccine preparations
Classe 9
next-generation sequencing (NGS) data processor; bioinformatics data processor; downloadable computer software for genome analysisdeveloping personal treatment strategies for patients with diagnosed canceranalyzingscreeningidentifyingquantifyinginterpreting data in the field of mass spectrometry
Classe 42
Providing temporary use of on-line nondownloadable software and applications for genome analysisdeveloping personal treatment strategies for patients with diagnosed cancer; conducting early evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technologycancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services for others in the field of designplanningimplementation of clinical trials; scientific research servicescollection of specific molecular and genomic data for analytical and clinical purposesfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biologycancer treatmentpharmaceutical side effectsgenomicscancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS)the analysis and interpretation of genomic data obtained from cancer patients; providing an onlinenon-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice
Classe 44
healthcare
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/06/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/06/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/06/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/06/2025
CCON
COUNTERCLAIM OPP. NO. 999999
26/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
23/11/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
21/10/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
21/10/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
20/10/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
18/10/2021
IUAF
USE AMENDMENT FILED
15/10/2021
EISU
TEAS STATEMENT OF USE RECEIVED
15/10/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
23/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/06/2021
EX5G
SOU EXTENSION 5 GRANTED
16/06/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
14/06/2021
NREV
NOTICE OF REVIVAL - E-MAILED
21/05/2021
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
20/05/2021
PETG
PETITION TO REVIVE-GRANTED
20/05/2021
PROA
TEAS PETITION TO REVIVE RECEIVED
20/05/2021
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
17/05/2021
ABN6
ABANDONMENT - NO USE STATEMENT FILED
17/05/2021
EXT5
SOU EXTENSION 5 FILED
16/04/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
16/10/2020
EX4G
SOU EXTENSION 4 GRANTED
14/10/2020
EXT4
SOU EXTENSION 4 FILED
14/10/2020
EEXT
SOU TEAS EXTENSION RECEIVED
14/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/08/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/08/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/03/2020
EX3G
SOU EXTENSION 3 GRANTED
10/03/2020
EXT3
SOU EXTENSION 3 FILED
10/03/2020
EEXT
SOU TEAS EXTENSION RECEIVED
10/03/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/10/2019
EX2G
SOU EXTENSION 2 GRANTED
02/10/2019
EXT2
SOU EXTENSION 2 FILED
02/10/2019
EEXT
SOU TEAS EXTENSION RECEIVED
02/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
27/03/2019
EX1G
SOU EXTENSION 1 GRANTED
25/03/2019
EXT1
SOU EXTENSION 1 FILED
25/03/2019
EEXT
SOU TEAS EXTENSION RECEIVED
25/03/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/10/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/08/2018
PUBO
PUBLISHED FOR OPPOSITION
21/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/07/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/07/2018
ALIE
ASSIGNED TO LIE
06/07/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/06/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/04/2018
GNRT
NON-FINAL ACTION E-MAILED
19/04/2018
CNRT
NON-FINAL ACTION WRITTEN
19/04/2018
DOCK
ASSIGNED TO EXAMINER
18/04/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/01/2018
NWAP
NEW APPLICATION ENTERED
12/01/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GRITSTONE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.